Washington, DC — December 23, 2022–Appropriations bills are not simply about funding. They are about people. That is why we are grateful that Congress prioritized funding for accelerated and disruptive Alzheimer’s disease research in the 2023 Omnibus Appropriations Bill.
Increases in funding for the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes of Health (NIH) are critical to addressing the increases in the number of cases of Alzheimer’s disease that we’ll face in the coming years. We applaud the commitment to health equity demonstrated by the support for institutions focused on serving people who are traditionally underserved, for solving health disparities in research and for the support for the INCLUDE Down Syndrome research initiative.
GAP expects that this funding, in combination with the work we and others are doing in communities across the country, will increase diversity in Alzheimer’s clinical research so that we can realize a treatment, prevention or cure that works for all of us. We champion the work of our federal partners in fighting this terrible disease. Thank you!